1. Home
  2. SSYS vs ARVN Comparison

SSYS vs ARVN Comparison

Compare SSYS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratasys Ltd. (Israel)

SSYS

Stratasys Ltd. (Israel)

HOLD

Current Price

$9.89

Market Cap

783.1M

Sector

Technology

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.62

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSYS
ARVN
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.1M
658.2M
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
SSYS
ARVN
Price
$9.89
$7.62
Analyst Decision
Strong Buy
Buy
Analyst Count
3
19
Target Price
$12.33
$15.05
AVG Volume (30 Days)
1.2M
816.7K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
$4.48
N/A
Revenue Next Year
$3.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$6.06
52 Week High
$12.78
$14.22

Technical Indicators

Market Signals
Indicator
SSYS
ARVN
Relative Strength Index (RSI) 59.08 23.63
Support Level $7.80 $7.35
Resistance Level $9.92 $8.22
Average True Range (ATR) 0.50 0.43
MACD 0.16 -0.09
Stochastic Oscillator 67.54 0.85

Price Performance

Historical Comparison
SSYS
ARVN

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: